Patients researching stem cell therapy will often come across two main sources: cells derived from umbilical cord tissue (UC-MSCs) and cells derived from fat tissue (adipose-derived stem cells, or ADSCs). Both fall under the category of mesenchymal stem cells. Both have been studied clinically. But they are not identical — and the differences between them are worth understanding before choosing a treatment.

What They Have in Common

UC-MSCs and ADSCs share a number of important characteristics. Both express the surface markers used to identify mesenchymal stem cells. Both can differentiate into bone, cartilage, and fat tissue under laboratory conditions. Both have demonstrated anti-inflammatory and immunomodulatory properties in clinical research. And both have been explored as alternatives to bone marrow-derived stem cells, which require more invasive harvesting procedures.

A side-by-side comparative study of UC-MSCs and ADSCs found that although the two cell types share considerable similarities in their immunological phenotype and multipotentiality, certain biological differences do exist — differences that may have meaningful implications for clinical outcomes depending on the condition being treated.

Where They Differ

Proliferation capacity

One of the most consistent findings across comparative studies is that UC-MSCs proliferate faster and maintain their growth capacity for longer than ADSCs. Research comparing umbilical cord blood-derived MSCs to adipose-derived MSCs found that UCB-MSCs could be cultured for significantly longer periods and exhibited the greatest expansion capacity, whereas ADSCs had the shortest culture time and lowest growth rate.

A separate study focused specifically on osteoarthritis confirmed that the proliferation of UC-MSCs was higher than that of ADSCs, consistent with larger pellet formation in chondrogenic induction conditions. In practical terms, higher proliferation capacity means more cells can be produced from a smaller starting quantity — which matters for dosage consistency across treatments.

Immunomodulatory signalling

UC-MSCs have been shown to secrete higher concentrations of immunomodulatory substances compared to other MSC sources. Research has found that UC-MSCs secrete higher concentrations of substances including IL-10, IL-8, TGF-β2, and HGF — molecules involved in regulating inflammation and supporting tissue repair. For conditions where immune modulation is a primary goal — such as autoimmune disorders or neurological conditions — this difference in paracrine activity may be clinically relevant.

Donor age and cell quality

ADSCs are typically autologous — meaning they come from the patient’s own fat tissue. This removes the question of immune compatibility, but it introduces another variable: the quality of the cells is tied directly to the donor’s age and health. In older patients, or those with chronic inflammation, the regenerative capacity of autologous cells may already be compromised.

UC-MSCs, by contrast, are allogeneic — sourced from young, healthy umbilical cord tissue collected at birth. The cells are from a biologically young source regardless of the patient’s age, and their low immunogenicity means the risk of rejection is minimal even when used across different donors.

Collection procedure

Harvesting ADSCs requires a liposuction procedure to collect fat tissue from the patient. This is minimally invasive but still a procedure with its own recovery period and variability in yield. UC-MSCs are collected from umbilical cord tissue that would otherwise be discarded after birth — making the collection process non-invasive for the recipient and ethically straightforward.

How They Compare for Specific Conditions

For osteoarthritis and joint conditions

Both UC-MSCs and ADSCs have shown meaningful results in osteoarthritis research. A study examining their effects on cartilage degeneration in an osteoarthritis model found that both cell types could significantly inhibit disease progression, with comparable chondrogenic potential in laboratory conditions. UC-MSCs demonstrated superior proliferation capacity, which may support more consistent dosing in clinical protocols.

For neurological and systemic conditions

UC-MSCs are more widely studied in the context of neurological and autoimmune conditions, in part because of their stronger immunomodulatory profile and their availability as a standardised allogeneic product. ADSCs have shown promise in cardiovascular and neurodegenerative research, though the evidence base for systemic use remains more limited compared to UC-MSCs.

Why Cell Source Is Not the Only Factor

Understanding the difference between UC-MSCs and ADSCs is useful, but it is only part of the picture. Cell source matters — but so does how the cells are prepared, what dosage is used, and the clinical context in which they are applied.

At EDNA Wellness, all UC-MSCs are sourced from a GMP-certified laboratory and tested before use. Cell quality is verified at the point of production, not assumed. This matters because the same cell type from different laboratories can vary significantly in viability, purity, and dosage accuracy — differences that affect outcomes regardless of which source is chosen.

Neither UC-MSCs nor ADSCs are universally superior. The right choice depends on the condition being treated, the patient’s overall health, and the clinical context. At EDNA Wellness, treatment decisions are made after a surgeon review of each case — not based on a single cell type being promoted as the default answer.

If you are weighing your options or have questions about which approach may be more appropriate for your situation, our team is available to discuss your case before any commitment is made.

About EDNA Wellness

EDNA Wellness is a surgeon-led regenerative medicine center in Bangkok, specializing in orthopedic and neurological conditions using Umbilical Cord–Derived Mesenchymal Stem Cells (UC-MSCs).

All cases are reviewed by orthopedic surgeons and neurosurgeons, with a focus on clinical indication, patient safety, and realistic treatment expectations. Stem cell therapy is recommended selectively, and alternative treatments are considered when more appropriate.

For more information or to book a consultation:

LINE: @ednawellness

WhatsApp: +66 (0) 64 505 5599

www.ednawellness.com

References

• Hmadcha A, et al. “Regenerative Capacity of Adipose Derived Stem Cells (ADSCs), Comparison with Mesenchymal Stem Cells (MSCs).” Frontiers in Bioengineering and Biotechnology. 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6566837/
• Yoo KH, et al. “Comparative Analysis of Human Mesenchymal Stem Cells from Bone Marrow, Adipose Tissue, and Umbilical Cord Blood as Sources of Cell Therapy.” International Journal of Molecular Sciences. 2013. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3794764/
• Wang M, et al. “Side-by-Side Comparison of the Biological Characteristics of Human Umbilical Cord and Adipose Tissue-Derived Mesenchymal Stem Cells.” BioMed Research International. 2013. https://pmc.ncbi.nlm.nih.gov/articles/PMC3722850/
• Shi Y, et al. “Comparison of biological characteristics of human adipose- and umbilical cord-derived mesenchymal stem cells and their effects on delaying the progression of osteoarthritis in a rat model.” PubMed. 2022. https://pubmed.ncbi.nlm.nih.gov/35764040/
• Ruiz M, et al. “Comparison of the paracrine activity of mesenchymal stem cells derived from human umbilical cord, amniotic membrane and adipose tissue.” PubMed. 2017. https://pubmed.ncbi.nlm.nih.gov/28707770/